Health Alert:

See the latest Coronavirus Information including testing sites, visitation restrictions, appointments and scheduling, and more.

In this first randomized clinical trial for intermediate-risk patients with severe, symptomatic AS, conducted by researchers in the Perelman School of Medicine at the University of Pennsylvania, in partnership with Edwards Lifesciences, the Cardiovascular Research Foundation, and 56 center across the United States and Canada, investigators found that TAVR with SAPIEN XT resulted in similar two-year clinical outcomes, as compared to surgical aortic valve replacement.

Share This Page: